InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,304.80
(
0.47%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.64
(
0.26%
)
Bitcoin
61,768.05
(
0.26%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: None

Monday, 06/07/2010 8:10:29 AM

Monday, June 07, 2010 8:10:29 AM

Post# of 252412
Ariad's "AP24534 represents a potential significant advance for CML patients who have become resistant to currently available therapies and who are in great need of new treatment options.”

http://finance.yahoo.com/news/ARIAD-Presents-Updated-bw-1341332663.html?x=0&.v=1

When one considers that Tasigna and Sprycel achieved 35% and 45% MCyR's in pts who failed Gleevec, AP534's 67% MCyR in pts with the T315I mutation is quite remarkable.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up